Properties of the EQ-5D-5L when prospective longitudinal data from 28,902 total hip arthroplasty procedures are applied to different European EQ-5D-5L value sets

被引:7
作者
Joelson, Anders [1 ,2 ]
Wildeman, Peter [1 ,2 ]
Sigmundsson, Freyr Gauti [1 ,2 ]
Rolfson, Ola [3 ,4 ,5 ]
Karlsson, Jan [6 ]
机构
[1] Orebro Univ, Sch Med Sci, Orebro, Sweden
[2] Orebro Univ Hosp, Dept Orthoped, Orebro, Sweden
[3] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Orthoped, Gothenburg, Sweden
[4] Sahlgrens Univ Hosp, Dept Orthoped, Gothenburg, Sweden
[5] Swedish Hip Arthroplasty Register, Gothenburg, Sweden
[6] Orebro Univ, Univ Hlth Care Res Ctr, Fac Med & Hlth, Orebro, Sweden
来源
LANCET REGIONAL HEALTH-EUROPE | 2021年 / 8卷
关键词
REPORTED OUTCOME MEASURES; COST-EFFECTIVENESS; VERSION; VALUATION; EUROQOL; IMPACT;
D O I
10.1016/j.lanepe.2021.100165
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The purpose of this study was to evaluate the impact of using different country-specific value sets in EQ-5D-5L based outcome analyses. Methods: We obtained data on patients surgically treated with total hip arthroplasty (THA) between 2017 and 2019 from the national Swedish Hip Arthroplasty Register. Preoperative and one-year postoperative data on a total of 28,902 procedures were available for analysis. The EQ-5D-5L health states were coded to the EQ-5D-5L preference indices using 13 European value sets. The EQ-5D-5L index distributions were then estimated with kernel density estimation. The change in EQ-5D-5L index before and one year after treatment was evaluated with the standardized response mean (SRM). The lifetime gain in quality-adjusted life years (QALYs) was estimated with a 3.5% annual QALY discount rate. Findings: There was a marked variability in means and shapes of the resulting EQ-5D-5L index distributions. There were also considerable differences in the EQ-5D-5L index distribution shape before and after the treat-ment using the same value set. The effect sizes of one-year change (SRM) were similar for all value sets. How-ever, the differences in estimated QALY gains were substantial. Interpretation: The EQ-5D-5L index distributions varied considerably when a single large data set was applied to different European EQ-5D-5L value sets. The most pronounced differences were between the value sets based on experience-based valuation and the value sets based on hypothetical valuation. This illustrates that experience-based and hypothetical value sets are inherently different and also that QALY gains derived with different value sets are not comparable. Our findings are of importance in study planning since the results and conclusions of a study depend on the choice of value set. Funding: None. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets
    Mulhern, Brendan
    Feng, Yan
    Shah, Koonal
    Janssen, Mathieu F.
    Herdman, Michael
    van Hout, Ben
    Devlin, Nancy
    PHARMACOECONOMICS, 2018, 36 (06) : 699 - 713
  • [2] A Comparison of PROPr and EQ-5D-5L Value Sets
    Pan, Tianxin
    Mulhern, Brendan
    Viney, Rosalie
    Norman, Richard
    Hanmer, Janel
    Devlin, Nancy
    PHARMACOECONOMICS, 2022, 40 (03) : 297 - 307
  • [3] EQ-5D-5L: a value set for Romania
    Olariu, Elena
    Mohammed, Wael
    Oluboyede, Yemi
    Caplescu, Raluca
    Niculescu-Aron, Ileana Gabriela
    Paveliu, Marian Sorin
    Vale, Luke
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2023, 24 (03) : 399 - 412
  • [4] The Indonesian EQ-5D-5L Value Set
    Purba, Fredrick Dermawan
    Hunfeld, Joke A. M.
    Iskandarsyah, Aulia
    Fitriana, Titi Sahidah
    Sadarjoen, Sawitri Supardi
    Ramos-Goni, Juan Manuel
    Passchier, Jan
    Busschbach, Jan J. V.
    PHARMACOECONOMICS, 2017, 35 (11) : 1153 - 1165
  • [5] An EQ-5D-5L Value Set for Vietnam
    Mai, Vu Quynh
    Sun, Sun
    Minh, Hoang Van
    Luo, Nan
    Giang, Kim Bao
    Lindholm, Lars
    Sahlen, Klas Goran
    QUALITY OF LIFE RESEARCH, 2020, 29 (07) : 1923 - 1933
  • [6] EQ-5D-5L Value Set for Slovenia
    Rupel, Valentina Prevolnik
    Ogorevc, Marko
    PHARMACOECONOMICS, 2023, 41 (11) : 1515 - 1524
  • [7] A Comparison of the EQ-5D-3L and EQ-5D-5L
    Thompson, Alexander James
    Turner, Alex James
    PHARMACOECONOMICS, 2020, 38 (06) : 575 - 591
  • [8] An EQ-5D-5L Value Set for Belgium
    Bouckaert, Nicolas
    Cleemput, Irina
    Devriese, Stephan
    Gerkens, Sophie
    PHARMACOECONOMICS-OPEN, 2022, 6 (06) : 823 - 836
  • [9] German Value Set for the EQ-5D-5L
    Ludwig, Kristina
    von der Schulenburg, J. -Matthias Graf
    Greiner, Wolfgang
    PHARMACOECONOMICS, 2018, 36 (06) : 663 - 674
  • [10] Estimating the EQ-5D-5L value set for the Philippines
    Miguel, Red Thaddeus D.
    Rivera, Adovich S.
    Cheng, Kent Jason G.
    Rand, Kim
    Purba, Fredrick Dermawan
    Luo, Nan
    Zarsuelo, Ma-Ann
    Julienne Genuino-Marfori, Anne
    Florentino-Farinas, Irene
    Melissa Guerrero, Anna
    Lam, Hilton Y.
    QUALITY OF LIFE RESEARCH, 2022, 31 (09) : 2763 - 2774